The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation

February 21, 2020 updated by: Christer Svensen, Karolinska Institutet

The Effect of Restrictive Fluid Management on Cardiac Function and Glycocalyx Degradation, a Preplanned Substudy of the CLASSIC Trial

The study aims to compare the effects of restrictive fluid management on cardiac dysfunction and vascular integrity in septic shock patients. To achieve this, patients with septic shock according to Sepsis-3 criteria admitted to several Intensive Care Units in Sweden and Denmark will be randomized to receive restrictive respectively standard fluid therapy. Blood test from these patients will be analyzed for several biomarkers of cardiac function and glycocalyx degradation. Echocardiography will also be performed to further investigate cardiac function.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Detailed Description

This study is a substudy to the larger CLASSIC-trial that aims to investigate restrictive and standard fluid therapy in treating septic shock. Adult patients with septic shock according to the Sepsis-3 criteria who have received at least 1 L of IV fluid in the 24 hours before screening will be screened. Patients who have had septic shock for more than 12 hours at the time of screening, who have life-threatening bleeding, or acute burn injury >10% of the body surface area, who are pregnant and those in whom consent cannot be obtained will be excluded. Blood samples will be drawn at T0 (during the first hour after enrolment), T1 (the first morning after inclusion) and T2 (the second morning) and T3 (at ICU discharge (within 24 hours before discharge)). The samples will be analyzed for high-sensitivity troponin T (hsTnT), pro-BNP, proAdrenomedulin (MR-proADM), Co-Peptin (AVP), endothelin-1 (ET-1), neuregulin-1 (NRG-1), growth differentiation factor-15 (GDF-15), metalloproteinases (MMPs), hyaluronan, syndecan-1, heparan sulfate, IL-6, TNFR and Ang-2.

Systolic and diastolic function parameters for the left and right heart will be collected at study enrolment (within 24 hours from inclusion) and at 2-3 and day 7-10 or at discharge using transthoracic or transesophageal echocardiography.

Baseline clinical and demographic data will be analyzed using chi-square or Fisher's exact test for categorical data, and the Wilcoxon rank-sum test for continuous data. The baseline and first follow-up measure of the concentration of a biomarker will be modelled using a mixed effect linear model with a person specific random effect and an interaction between time of follow-up measure (interval since first measurement) and treatment group, the stratification variables for the randomization: hematological or metastatic cancer (Y/N) and trial site as fixed effects. A mixed model will be used to analyze the pattern of biomarkers over time. Differences between intervention groups will be tested by the interaction of time and group in the same mixed model analyses. Additional covariates will be added to adjust for treating center, illness severity (SMS-score), cumulative fluid balance and comorbidities.

The investigators have based sample size calculations on both primary outcomes, hsTnT and hyaluronan concentrations, and estimated predicted differences and standard deviations found in previous comparable studies. The Jakobsen-Lange will be used to adjust for two outcomes where αi for each outcome is αi=0.05/((n+1)/2) = 0,033 which is an adjustment halfway between no adjustment and full Bonferroni adjustment with n being the number of co-primary outcomes and secondary outcomes respectively. For sample size calculations a power of 80 % will be used. Using a standard deviation of 40 ng/l of hsTnT this reveals a sample size of n=120 to detect a group difference of 22 ng/l. To account for drop-out and loss-to-follow-up an extra 10% will be added, 132 patients will be included equally distributed between the two groups. Using a standard deviation of 29 ng/ml of hyaluronan concentration reveals a sample size of n=225 to detect a group difference of 11,5 ng/ml. To account for drop-out and loss-of-follow-up an extra 10% will be added, 248 patients will be included equally distributed between the two groups.

Study Type

Interventional

Enrollment (Anticipated)

132

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

- Patients with septic shock according to the Sepsis-3 criteria who have received at least 1 L of IV fluid in the 24 hours before screening

Exclusion Criteria:

  • Patients who have had septic shock for more than 12 hours at the time of screening
  • Patients who have life-threatening bleeding
  • Patients with acute burn injury >10% of the body surface area
  • Pregnant patients
  • Patients in whom consent cannot be obtained

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: IV fluid restriction group

No IV fluids should be given unless one of the below occurs; in these cases, IV fluid may be given:

  1. In case of severe hypoperfusion or severe circulatory impairment defined by:

    Lactate 4 mmol/L or above or mean arterial blood pressure below 50 mm Hg or mottling beyond the kneecap or urinary output less than 0.1 mL/kg bodyweight/h, but only in the first 2 hours after randomisation. A bolus of 250-500 mL of IV crystalloid solution may be given.

  2. In case of overt fluid losses (eg, vomiting, large aspirates, diarrhoea, drain losses, bleeding or ascites tap) IV fluid may be given to correct for the loss.
  3. In case the oral/enteral route for water or electrolyte solutions is contraindicated or has failed, IV fluids may be given to correct dehydration or electrolyte imbalances and/or to ensure a total fluid input of 1 L per 24 hours.
All i.v. fluids used in an Intensive Care Unit.
Active Comparator: Standard care group
There will be no upper limit for the use of IV or oral/enteral fluids. In particular: IV fluids should be given in the case of hypoperfusion or circulatory impairment and should be continued as long as hemodynamic variables improve including static or dynamic variable(s) as chosen by the clinicians. These criteria are based on the Surviving Sepsis Campaign guideline. IV fluids should be given as maintenance if the ICU has a protocol recommending maintenance fluid. IV fluids should be given to substitute expected or observed loss, dehydration or electrolyte imbalances.
All i.v. fluids used in an Intensive Care Unit.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myocardial injury
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
To investigate if IV fluid restriction decreases myocardial injury measured as plasma highly sensitive Troponin T (hsTnT) concentrations.
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
Hyaluronan levels
Time Frame: First morning after enrolment (within 24 hours from enrollment)
To study the effect of conservative fluid management versus standard care on the glycocalyx by measuring the levels of hyaluronan.
First morning after enrolment (within 24 hours from enrollment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Left ventricular systolic function, MAPSE
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
To assess the effect of IV conservative fluid management on left ventricular systolic function measured as difference in mitral annular plane systolic excursion measured in millimeters using echocardiography.
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
Difference in Syndecan-1 levels
Time Frame: First morning after enrolment (within 24 hours from enrollment)
To compare the difference in concentration of syndecan-1 at the first morning after enrolment (T1) in the conservative fluid management group versus standard care group, adjusted for the T0 values.
First morning after enrolment (within 24 hours from enrollment)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Left ventricular systolic function, global longitudinal strain
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
To investigate if conservative fluid management improves left ventricular strain measured in per cent using echocardiography.
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
Effect of a conservative fluid management strategy on C-terminal pro-endothelin-1 (CT-proET-1) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
To investigate the effect of a conservative fluid management strategy on C-terminal pro-endothelin-1 (CT-proET-1) concentrations in pmol/L.
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
Effect of a conservative fluid management strategy on neuregulin-1 (NRG-1) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
To investigate the effect of a conservative fluid management on neuregulin-1 (NRG-1) concentrations in ng/ml.
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
Effect of a conservative fluid management strategy on mid-regional pro-adrenomedullin (MR-proADM) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
To investigate the effect of a conservative fluid management strategy mid-regional pro-adrenomedullin (MR-proADM) in nmol/l.
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
Effect of a conservative fluid management strategy on Growth differentiation factor-15 (GDF-15) concentrations.
Time Frame: Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
To investigate the effect of a conservative fluid management strategy on concentrations of Growth differentiation factor-15 (GDF-15) in pg/ml.
Compare result within 24 hours of enrolment with day 2-3 and day 7-10 or at discharge
Association between glycocalyx hyaluronan concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
To analyze the association between hyaluronan concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
Day 3 after randomization
Association between heparan sulfate concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
To analyze the association between heparan sulfate concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
Day 3 after randomization
Association between syndecan-1 concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
To analyze the association between syndecan-1 concentrations (pg/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
Day 3 after randomization
Association between Tumor Necrosis Factor Receptor concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
To analyze the association between Tumor Necrosis Factor Receptor concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
Day 3 after randomization
Association between IL-6 concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
To analyze the association between IL-6 concentrations (pg/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
Day 3 after randomization
Association between Angiopoetin-2 concentrations and cumulative fluid balance day three/patient weight, separately in each randomization group
Time Frame: Day 3 after randomization
To analyze the association between Angiopoetin-2 concentrations (ng/ml) at inclusion with cumulative fluid balance day 3/patient weight (ml/kg), corrected for fluid volumes given before randomization, separately in each randomization group.
Day 3 after randomization
Glycocalyx integrity defined by levels of heparan sulfate.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
To compare the difference in concentration of heparan sulfate at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
First morning after enrollment (within 24 hours from enrollment)
Glycocalyx integrity defined by levels of IL-6.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
To compare the difference in concentration of IL-6 at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
First morning after enrollment (within 24 hours from enrollment)
Glycocalyx integrity defined by levels of TNFR.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
To compare the difference in concentration of TNFR at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
First morning after enrollment (within 24 hours from enrollment)
Glycocalyx integrity defined by levels of Ang-2.
Time Frame: First morning after enrollment (within 24 hours from enrollment)
To compare the difference in concentration of Ang-2. at the first morning after enrolment(T1) in the restrictive group compared with the control group, adjusted for the T0 values.
First morning after enrollment (within 24 hours from enrollment)
Left ventricular systolic function, LVEF
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
To investigate if conservative fluid management improves left ventricular ejection fraction measured in per cent using echocardiography.
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
Left ventricular systolic function, TDI
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
To investigate if conservative fluid management improves left ventricular tissue doppler index measured in cm/s using echocardiography.
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
Right ventricular systolic function, TDI
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
To investigate if conservative fluid management improves right ventricular tissue doppler index measured in cm/s using echocardiography.
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
Right ventricular systolic function, TAPSE
Time Frame: Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge
To investigate if conservative fluid management improves right annular plane systolic excursion measured in mm using echocardiography.
Compare result within 24 hours of enrollment with day 2-3 and day 7-10 or at discharge

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Maria Cronhjort, MD, PhD, Karolinska Institutet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

February 24, 2020

Primary Completion (Anticipated)

October 1, 2021

Study Completion (Anticipated)

April 1, 2022

Study Registration Dates

First Submitted

January 31, 2020

First Submitted That Met QC Criteria

February 21, 2020

First Posted (Actual)

February 24, 2020

Study Record Updates

Last Update Posted (Actual)

February 24, 2020

Last Update Submitted That Met QC Criteria

February 21, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Septic Shock

Clinical Trials on I.V. SOLUTIONS

3
Subscribe